Eisai files for full FDA approval for Alzheimer's drug Leqembi

The logo of Eisai Co Ltd is displayed at the company headquarters in Tokyo
The logo of Eisai Co Ltd is displayed at the company headquarters in Tokyo, Japan, March 8, 2018. REUTERS/Issei Kato

Jan 6 (Reuters) - Japanese drugmaker Eisai Co Ltd (4523.T) said on Saturday it had submitted an application to the U.S. Food and Drug Administration for a standard review of its Alzheimer's drug Leqembi, which was recently approved under the agency's accelerated review process.

Reporting by Bhanvi Satija in Bengaluru; Editing by William Mallard

Our Standards: The Thomson Reuters Trust Principles.